404
+1-313-307-4176
Sunitinib Malate Market Report
Sunitinib Malate Market Size, Share, Trend, Forecast, & Industry Analysis: 2021-2026
Sunitinib malate is known as the orally bioavailable malate salt of an indolinone-based tyrosine kinase inhibitor. Based on purity, sunitinib malate can be categorized as >99%, >98%, and >97%. It is a small-molecule inhibitor of multiple receptor tyrosine kinases involved in cancer.
The Sunitinib Malate market is projected to grow from USD xx billion in 2020 to USD xx billion by 2026 at a CAGR of around x% during the forecast period.
|
Sunitinib Malate market - Research Scope |
|
|---|---|
|
Base Year of Study |
2020 |
|
Trend Period |
2015-2019 |
|
Forecast Period |
2021-2026 |
|
Market Size in 2020 |
USD xx million |
|
Market Size in 2026 |
USD xx million |
|
Market Growth (2021-2026) |
x% CAGR |
The growth of the sunitinib malate market is driven by the increasing prevalence of the gastrointestinal disorder. Expanding geriatric populace coupled with rising cases of pancreatic cancer is expected to drive the market growth at a significant rate. In addition to this, increasing investment in R&D activities for new drug development is likely to create lucrative opportunities for the players operating in the global market during the review period.
The covid-19 outbreak posed significant challenges across verticals worldwide. Supply chain disruptions due to the imposition of lockdown affected the product availability on time and thus, affected the market growth.
Based on application, the market has been segmented into pancreatic neuroendocrine tumors, kidney cancer, and gastrointestinal stromal tumor. Among these, the pancreatic neuroendocrine tumors segment accounted for the largest market share in 2020 and is expected to propel market growth at a significant rate during the review period. The segment growth can be attributed to the increasing number of people suffering from pancreatic cancer disease.
The market in the North American region accounted for the largest market share in 2020 and is expected to grow at a healthy CAGR during the review period. The regional market growth can be attributed to the prevalence of a large number of people suffering from chronic kidney diseases and the presence of key market players such as Pfizer Inc. (US) and Top Care Pharmacy (US). The market in Asia-Pacific is expected to register significant growth on account of increasing incidences of gastrointestinal disorders, particularly in developing countries.
This market research report provides in-depth information on trends, dynamics, revenue opportunities, competitive landscape, and recent developments in the global Sunitinib Malate market. The historic years considered for the study are 2016-2019, the base year is 2020, and the forecast period is 2021-2026. Following are the critical questions answered in the report-
Key players operating in the Sunitinib Malate market are-
Here is the list of the group of customers that the sunitinib malate market hopes to have the greatest opportunity to convert-
Custom Research: Stratview research offers custom research services across sectors. In case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please send your inquiry at [email protected].
The report is delivered digitally through our online portal. Buyers receive login credentials from our team to access the report and may update their credentials at any time after the initial login.
Delivery timelines depend on the status of the report:
For the most accurate delivery timeline, please contact us to confirm the current status of the report.
Yes. You may request a complimentary preview of the report through a video conference with our team.
Yes. The scope of the report can be fully customized to align with your specific research objectives and information requirements.
Please contact us at [email protected], and our team will be happy to discuss your requirements and propose a tailored solution.
Yes. Selected sections of the report can be purchased separately based on your requirements. Please contact us at [email protected] to discuss your needs.
Yes, AI can help gather publicly available information, but its outputs are only as reliable as the data it accesses. Stratview Research reports are built using validated data, extensive primary interviews with industry stakeholders, and the expertise of our experienced research team.
Additionally, many critical insights, including market dynamics, competitive intelligence, and industry-specific trends, are not publicly available and therefore cannot be captured through AI alone.
Pfizer Inc. (US), Top Care Pharmacy (US), J&K Scientific (China), Targetmol (US), Active Biotech AB (Sweden), Astellas Pharma Inc. (Japan), AstraZeneca plc (UK), Bristol Myers Squibb (US), Dendreon (US), Endo International plc (Ireland) and Ferring Pharmaceuticals Inc. (US) are among the key players in the sunitinib market.
Increasing prevalence of the gastrointestinal disorder, expanding geriatric populace coupled with rising cases of pancreatic cancer are the factors driving the growth of sunitinib market.
The pancreatic neuroendocrine tumors segment accounted for the largest share in the sunitinib market in 2020.
North America is expected to grow at a healthy CAGR in the sunitinib market in the next five years.
Sunitinib malate distributors, Sunitinib malate suppliers, Sunitinib malate manufacturers, Logistics organizations, Government bodies are the target audience in the sunitinib market.
WE ACCEPT
